WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Friday, December 16, 2005

Hide?	Set Name	Query	Hit Count
		DB=PGPB,USPT; PLUR=YES; OP=OR	
☐	L2	L1 and antibod?	105
☐	L1	(pdgf adj c or fallotein or scdgf adj b or pdgf adj d)	124

END OF SEARCH HISTORY

WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Friday, December 16, 2005

Hide?	Set Name	Query	Hit Count
		DB=EPAB,JPAB,DWPI; PLUR=YES; OP=OR	
☐	L9	(zvegf4 or pdgf adj c or fallotein or scdgfb or scdgf adj b or pdgf adj d)	29

END OF SEARCH HISTORY

WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Friday, December 16, 2005

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT; PLUR=YES; OP=OR		
☐	L8	L7 and (zvegf4 or pdgf adj c or fallotein or scdgfb or scdgf adj b or pdgf adj d)	30
☐	L7	GILBERTSON	1109
☐	L6	L5 and (zvegf4 or pdgf adj c or fallotein or scdgfb or scdgf adj b or pdgf adj d)	6
☐	L5	TOPOUZIS	15
☐	L4	L2 and (zvegf4 or pdgf adj c or fallotein or scdgfb or scdgf adj b or pdgf adj d)	31
☐	L3	L2 and (zvegf4 or pdgf adj c or falltein or scdgfb or scdgf adj b or pdgf adj d)	31
☐	L2	HART	31570
☐	L1	5094941	42

END OF SEARCH HISTORY

```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssptacmb1647

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2          "Ask CAS" for self-help around the clock
 NEWS  3  SEP 09  ACD predicted properties enhanced in REGISTRY/ZREGISTRY
 NEWS  4  OCT 03  MATHDI removed from STN
 NEWS  5  OCT 04  CA/CAplus-Canadian Intellectual Property Office (CIPO) added
                  to core patent offices
 NEWS  6  OCT 13  New CAS Information Use Policies Effective October 17, 2005
 NEWS  7  OCT 17  STN(R) AnaVist(TM), Version 1.01, allows the export/download
                  of CAplus documents for use in third-party analysis and
                  visualization tools
 NEWS  8  OCT 27  Free KWIC format extended in full-text databases
 NEWS  9  OCT 27  DIOGENES content streamlined
 NEWS 10  OCT 27  EPFULL enhanced with additional content
 NEWS 11  NOV 14  CA/CAplus - Expanded coverage of German academic research
 NEWS 12  NOV 30  REGISTRY/ZREGISTRY on STN(R) enhanced with experimental
                  spectral property data
 NEWS 13  DEC 05  CASREACT(R) - Over 10 million reactions available
 NEWS 14  DEC 14  2006 MeSH terms loaded in MEDLINE/LMEDLINE
 NEWS 15  DEC 14  2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
 NEWS 16  DEC 14  CA/CAplus to be enhanced with updated IPC codes

 NEWS EXPRESS  DECEMBER 02 CURRENT VERSION FOR WINDOWS IS V8.01,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 02 DECEMBER 2005.
               V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
               http://download.cas.org/express/v8.0-Discover/

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:00:07 ON 16 DEC 2005

=> file medline biosis embase caplus
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
```

```
                                                        ENTRY     SESSION
FULL ESTIMATED COST                                      0.21        0.21

FILE 'MEDLINE' ENTERED AT 11:00:44 ON 16 DEC 2005

FILE 'BIOSIS' ENTERED AT 11:00:44 ON 16 DEC 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 11:00:44 ON 16 DEC 2005
Copyright (c) 2005 Elsevier B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 11:00:44 ON 16 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> s (zvegf4 or pdgf(w)c or fallotein or scdgfb or scdgf(w)b or pdgf(w)d or zvegf3)
L1          346 (ZVEGF4 OR PDGF(W) C OR FALLOTEIN OR SCDGFB OR SCDGF(W) B OR
                PDGF(W) D OR ZVEGF3)

=> s l1 and antibod?
L2           65 L1 AND ANTIBOD?

=> dup rem
ENTER L# LIST OR (END):l2
PROCESSING COMPLETED FOR L2
L3           41 DUP REM L2 (24 DUPLICATES REMOVED)

=> dis ibib abs l3 30-41

L3   ANSWER 30 OF 41  CAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:         2002:540192  CAPLUS
DOCUMENT NUMBER:          137:104171
TITLE:                    PDGF D polypeptides, nucleic acids
                          encoding them, and therapeutic or diagnostic
                          applications of the polypeptides or their
                          antibodies
INVENTOR(S):              Shimkets, Richard A.; Lichenstein, Henri; Herrmann,
                          John L.; Boldog, Ferenc L.; Minskoff, Stacey; Jeffers,
                          Michael; Andrews, David; La Rochelle, William
PATENT ASSIGNEE(S):       USA
SOURCE:                   U.S. Pat. Appl. Publ., 97 pp., Cont.-in-part of U.S.
                          Ser. No. 715,332.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   160
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     --------------       ----   --------    --------------------     --------
     US 2002094546         A1    20020718    US 2001-775482           20010202
     WO 2002059618         A2    20020801    WO 2001-US48901          20011116
     WO 2002059618         A3    20030508
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
             UG, US, UZ, VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
             GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
             GN, GQ, GW, ML, MR, NE, SN, TD, TG
```

PRIORITY APPLN. INFO.:

US 1999-158083P	P	19991007
US 1999-159231P	P	19991013
US 2000-174485P	P	20000104
US 2000-186707P	P	20000303
US 2000-188250P	P	20000310
US 2000-223879P	P	20000808
US 2000-234082P	P	20000920
US 2000-688312	A2	20001013
US 2000-715332	A2	20001116

AB Disclosed are novel PDGFD nucleic acids encoding proteins and polypeptides related to bone morphogenetic protein-1 (BMF1), to vascular endothelial growth factor E (VEGF-E) and to platelet derived growth factor (PDGF). Also disclosed are vectors, host cells, **antibodies**, and recombinant methods for producing these nucleic acids and polypeptides. Methods of use include detecting and staging of cancers. The claims of this continuation-in-part patent specifically claim a method of detecting the presence of at least one PDGFD antigen in a sample, comprising the steps of: (a) providing a biol. sample; (b) contacting the sample with an agent that binds the antigen; and (c) detecting the presence of the agent bound to the antigen; whereby the presence of the agent indicates that the antigen is present in the sample. A method contributing to a diagnosis of cancer in a subject based on the presence of a PDGFD antigen in a sample from the subject is also claimed, as is a method of staging cancer in a subject. Addnl. claimed are a method of phosphorylating a tyrosine residue of a cellular receptor comprising the step of contacting a cell harboring the receptor with a PDGFD polypeptide, a method of stimulating a response in a cell that is specific for a PDGF beta receptor comprising contacting the cell with a PDGFD polypeptide, and a method of inhibiting the growth of a cell by contacting the cell with an agent that specifically binds a PDGFD polypeptide. An isolated nucleic acid comprising a sequence encoding a PDGFD polypeptide and a method of preparing the PDGFD polypeptide are also claimed.

L3 ANSWER 31 OF 41 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:409185 CAPLUS
DOCUMENT NUMBER: 137:5012
TITLE: Anti-**zvegf4 antibodies**, **zvegf4** antagonists, and antisense polynucleotides for treating fibroproliferative disorders
INVENTOR(S): Hart, Charles E.; Topouzis, Stavros; Gilbertson, Debra G.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 34 pp., Cont.-in-part of U. S. Ser. No. 564,595.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002064832	A1	20020530	US 2001-808972	20010314
US 6630142	B2	20031007		
US 6495668	B1	20021217	US 2000-564595	20000503
US 2004002140	A1	20040101	US 2001-876813	20010606
US 6962802	B2	20051108		
US 2003105015	A1	20030605	US 2002-226559	20020823
US 6866991	B2	20050315		
US 2004043027	A1	20040304	US 2003-606055	20030625
US 2004242850	A1	20041202	US 2004-877623	20040625
US 2005031694	A1	20050210	US 2004-910938	20040803
US 2005164937	A1	20050728	US 2005-80803	20050315

PRIORITY APPLN. INFO.:

US 1999-132250P	P	19990503
US 1999-164463P	P	19991110
US 2000-180169P	P	20000204
US 2000-564595	A2	20000503
US 2000-235295P	P	20000926
US 2000-540224	A3	20000331
US 2001-808972	A3	20010314
US 2001-876813	A3	20010606
US 2002-226559	A1	20020823

AB Materials and methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a **zvegf4** protein antagonist in combination with a pharmaceutically acceptable delivery vehicle. Exemplary **zvegf4** antagonists include anti-**zvegf4 antibodies**, inhibitory polynucleotides, inhibitors of **zvegf4** activation, and mitogenically inactive, receptor-binding variants of **zvegf4**. The materials and methods are useful in the treatment of, inter alia, fibroproliferative disorders of the kidney, liver, and bone.

L3 ANSWER 32 OF 41 MEDLINE on STN DUPLICATE 7
ACCESSION NUMBER: 2002242895 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11980634
TITLE: Platelet-derived growth factor D: tumorigenicity in mice and dysregulated expression in human cancer.
AUTHOR: LaRochelle William J; Jeffers Michael; Corvalan Jose R F; Jia Xiao-Chi; Feng Xiao; Vanegas Sandra; Vickroy Justin D; Yang Xiao-Dong; Chen Francine; Gazit Gadi; Mayotte Jane; Macaluso Jennifer; Rittman Beth; Wu Frank; Dhanabal Mohan; Herrmann John; Lichenstein Henri S
CORPORATE SOURCE: CuraGen Corp., Branford, Connecticut 06405, USA.. wlarochelle@curagen.com
SOURCE: Cancer research, (2002 May 1) 62 (9) 2468-73. Journal code: 2984705R. ISSN: 0008-5472.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200205
ENTRY DATE: Entered STN: 20020501
Last Updated on STN: 20020602
Entered Medline: 20020531

AB Platelet-derived growth factor (PDGF) has been directly implicated in developmental and physiological processes, as well as in human cancer and other proliferative disorders. We have recently isolated and characterized a novel protease-activated member of the PDGF family, **PDGF D**. **PDGF D** has been shown to be proliferative for cells of mesenchymal origin, signaling through PDGF receptors. Comprehensive and systematic **PDGF D** transcript analysis revealed expression in many cell lines derived from ovarian, renal, and lung cancers, as well as from astrocytomas and medulloblastomas. beta PDGF receptor profiling further suggested autocrine signaling in several brain tumor cell lines. **PDGF D** transforming ability and tumor formation in SCID mice was further demonstrated. Exploiting a sensitive **PDGF D** sandwich ELISA using fully human monoclonal **antibodies**, **PDGF D** was detected at elevated levels in the sera of ovarian, renal, lung, and brain cancer patients. Immunohistochemical analysis confirmed **PDGF D** localization to ovarian and lung tumor tissues. Together, these data demonstrate that **PDGF D** plays a role in certain human cancers.

L3 ANSWER 33 OF 41 MEDLINE on STN DUPLICATE 8
ACCESSION NUMBER: 2002667552 MEDLINE

DOCUMENT NUMBER: PubMed ID: 12427128
TITLE: Platelet-derived growth factor-D expression in developing and mature human kidneys.
AUTHOR: Changsirikulchai Siribha; Hudkins Kelly L; Goodpaster Tracy A; Volpone John; Topouzis Stavros; Gilbertson Debra G; Alpers Charles E
CORPORATE SOURCE: Department of Medicine, Srinakharinwirot University, Bangkok, Thailand.
CONTRACT NUMBER: DK47959 (NIDDK)
SOURCE: Kidney international, (2002 Dec) 62 (6) 2043-54. Journal code: 0323470. ISSN: 0085-2538.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
OTHER SOURCE: GENBANK-AF336376
ENTRY MONTH: 200305
ENTRY DATE: Entered STN: 20021113
Last Updated on STN: 20030524
Entered Medline: 20030523

AB BACKGROUND: Platelet-derived growth factor (PDGF) is a family of growth regulatory molecules composed of sulfide-bonded dimeric structures. Two well-studied PDGF peptides (PDGF-A and PDGF-B) have been shown to mediate a wide range of biological effects. **PDGF-D** is a newly recognized member of the PDGF family. Initial studies of the **PDGF-D** gene found its expression in cells of the vascular wall, suggesting that it could participate in vascular development and pathology. However, its localization in human kidney tissues has never been studied. METHODS: **PDGF-D** expression in fetal (N = 30) and adult (N = 25) human kidney tissues was examined by immunohistochemistry using an affinity-purified **antibody** raised to human **PDGF-D**. **Antibody** absorption with the immunizing peptide was employed to confirm the specificity of this **antibody**. **PDGF-D** protein and gene expression in human kidneys also were demonstrated by Western blotting and reverse transcription-polymerase chain reaction (RT-PCR). RESULTS: In the developing kidney, **PDGF-D** was first expressed by epithelial cells of comma- and S-shaped structures of the developing nephron, and most consistently in the visceral epithelial cells in the later stages of glomerular differentiation. In addition, **PDGF-D** could be found in mesenchymal, presumptively fibroblast cells in the interstitium of developing renal pelvis and in fetal smooth muscle cells in arterial vessels. In the adult normal kidney, **PDGF-D** was expressed by the visceral epithelial cells. There was persistent expression in arterial smooth muscle cells as well as in some neointimal smooth muscle cells of arteriosclerotic vessels, and expression in smooth muscle cells of vasa rectae in the medulla. **PDGF-D** could be identified at the basolateral membrane of some injured tubules in areas of chronic tubulointerstitial injury routinely encountered in aging kidneys. Western blotting of homogenates of adult kidneys demonstrated monospecific bands at 50 kD corresponding to previously established size parameter for this protein. RT-PCR of human kidney RNA resulted in a 918 basepair band, the sequence of which corresponded to human **PDGF-D** (Genbank number AF336376). CONCLUSIONS: To our knowledge, these are the first studies to localize **PDGF-D** in human kidneys and suggest that **PDGF-D** may have a role in kidney development. **PDGF-D** was shown to bind to PDGF beta receptor, which localizes to mesangial cells, parietal epithelial cells, and interstitial fibroblasts, suggesting potential paracrine interactions between those cells and the visceral epithelium.

L3 ANSWER 34 OF 41 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:231900 CAPLUS

DOCUMENT NUMBER: 137:227182
TITLE: Mice with Cre recombinase activatable PDGF-C expression
AUTHOR(S): Ding, Hao; Wu, Xiaoli; Nagy, Andras
CORPORATE SOURCE: Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON, M5G 1X5, Can.
SOURCE: Genesis (New York, NY, United States) (2002), 32(2), 181-183
CODEN: GNESFY; ISSN: 1526-954X
PUBLISHER: Wiley-Liss, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The recent discovery of two new platelet-derived growth factor (PDGF) family members, **PDGF-C** and **PDGF-D**, suggests that the functional complexity of the PDGF family is larger than previously thought. To analyze the consequences of ectopic or overexpression of **PDGF-C**, the authors present the establishment of conditional transgenic mice that express **PDGF-C** in a Cre-excision conditional manner. Western blot anal. with anti-Flag **antibody** showed two **PDGF-C** isoforms in double transgenic embryos, i.e., the full-length 55 kDa and the protease-activated 23 kDa isoform. Preliminary observation of midgestation double transgenic embryos indicated that biol. activity of transgenic **PDGF-C** caused developmental defects, including facial abnormalities.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 35 OF 41 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:300544 CAPLUS
DOCUMENT NUMBER: 134:325212
TITLE: Method of treating fibrosis
INVENTOR(S): Gilbertson, Debra G.
PATENT ASSIGNEE(S): Zymogenetics, Inc., USA
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001028586	A1	20010426	WO 2000-US29270	20001023
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000080317	A5	20010430	AU 2000-80317	20001023
US 6893637	B1	20050517	US 2000-695121	20001023
US 2003087870	A1	20030508	US 2002-264361	20021003
US 2005049218	A1	20050303	US 2004-938375	20040910
PRIORITY APPLN. INFO.:			US 1999-161653P	P 19991021
			US 1999-165255P	P 19991112
			US 2000-222223P	P 20000801
			US 2000-695121	A1 20001023
			WO 2000-US29270	W 20001023

AB Materials and methods for treating fibrosis in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a

therapeutically effective amount of a **zvegf3** antagonist in combination with a pharmaceutically acceptable delivery vehicle. **Zvegf3** antagonists include anti-**zvegf3** **antibodies**, mitogenically inactive receptor-binding **zvegf3** variant polypeptides, and inhibitory polynucleotides. Within one embodiment of the invention the fibrosis is liver fibrosis.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 36 OF 41 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:790635 CAPLUS
DOCUMENT NUMBER: 133:345605
TITLE: Protein and cDNA sequences of novel human and mouse vascular endothelial growth factor zvegf-4 and diagonistic and therapeutic uses thereof
INVENTOR(S): Gilbert, Teresa; Hart, Charles E.; Sheppard, Paul O.; Gilbertson, Debra G.
PATENT ASSIGNEE(S): Zymogenetics, Inc., USA
SOURCE: PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000066736	A1	20001109	WO 2000-US40047	20000503
WO 2000066736	B1	20001221		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2370948	AA	20001109	CA 2000-2370948	20000503
EP 1177293	A1	20020206	EP 2000-928993	20000503
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002542825	T2	20021217	JP 2000-615760	20000503
US 2003105015	A1	20030605	US 2002-226559	20020823
US 6866991	B2	20050315		
US 2004242850	A1	20041202	US 2004-877623	20040625
US 2005031694	A1	20050210	US 2004-910938	20040803
US 2005164937	A1	20050728	US 2005-80803	20050315

PRIORITY APPLN. INFO.:		
US 1999-304216	A	19990503
US 1999-164463P	P	19991110
US 2000-180169P	P	20000204
US 1999-132250P	P	19990503
US 2000-540224	A3	20000331
US 2000-564595	A3	20000503
WO 2000-US40047	W	20000503
US 2001-876813	A3	20010606
US 2002-226559	A1	20020823

AB The present invention provides protein and cDNA sequences for a newly identified human and mouse vascular endothelial growth factor, designated zvegf-4, which is cloned from a human chronic myelogenous leukemia cell and mouse genomic library by its homol. to the VEGF family. The vascular endothelial growth factor zvegf-4 resides on human chromosome 11 at 11q22.3-q23.1. The invention also relates to the tissue distribution of zvegf-4 mRNA. The present invention also includes **antibodies** to zvegf-4. The sequences of zvegf-4, may be used for detecting human

disease associated with zvegf-4 activities, and as a therapeutic.
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 37 OF 41 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:535282 CAPLUS
DOCUMENT NUMBER: 133:145921
TITLE: Human platelet-derived growth factor/vascular endothelial growth factor-like growth factor H, its cDNA sequences and therapeutic applications
INVENTOR(S): Eriksson, Ulf; Alitalo, Kari; Lauren, Juha
PATENT ASSIGNEE(S): Ludwig Institute for Cancer Research, USA; Helsinki University Licensing Ltd.
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000044903	A1	20000803	WO 2000-US1895	20000128
W: AU, CA, CN, JP, KR, NZ, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1147193	A1	20011024	EP 2000-915701	20000128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002535006	T2	20021022	JP 2000-596145	20000128
PRIORITY APPLN. INFO.:			US 1999-117864P P	19990129
			WO 2000-US1895 W	20000128

AB A portion of the PDGF/VEGF-Like Growth Factor H, a new member of the VEGF family of growth factors, is described, as well as its cDNA sequences. Methods for expressing and producing it, analyzing its function, preparing its **antibodies** and screening for its antagonists for medical and diagnostic applications are also provided.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 38 OF 41 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:401998 CAPLUS
DOCUMENT NUMBER: 133:38714
TITLE: **ZVEGF3**: a homolog of vascular endothelial growth factor and its use
INVENTOR(S): Gao, Zeren; Hart, Charles E.; Piddington, Christopher S.; Sheppard, Paul O.; Shoemaker, Kimberly E.; Gilbertson, Debra G.; West, James W.
PATENT ASSIGNEE(S): Zymogenetics, Inc., USA
SOURCE: PCT Int. Appl., 173 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000034474	A2	20000615	WO 1999-US28968	19991207
WO 2000034474	A3	20001228		
WO 2000034474	C2	20020829		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,				

MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2354325	AA	20000615	CA 1999-2354325	19991207
EP 1137773	A2	20011004	EP 1999-966032	19991207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002531127	T2	20020924	JP 2000-586908	19991207
AU 764039	B2	20030807	AU 2000-21679	19991207
AU 2000021679	A5	20000626		
US 2003087870	A1	20030508	US 2002-264361	20021003
US 2005049218	A1	20050303	US 2004-938375	20040910
PRIORITY APPLN. INFO.:			US 1998-207120 A	19981207
			US 1999-142576P P	19990706
			US 1999-161653P P	19991021
			US 1999-165255P P	19991112
			WO 1999-US28968 W	19991207
			US 2000-222223P P	20000801
			US 2000-695121 A1	20001023

AB A protein that shows sequence similarities to the vascular endothelial growth factors and that may be of therapeutic use is identified and characterized using them are disclosed. The polypeptides comprises an amino acid segment that is at least 90% identical to residues 46-163 of SEQ ID NO:2 or residues 235-345 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents. The gene was identified in public EST databases and a cDNA cloned by PCR from a human salivary gland cDNA library. Ectopic expression of the gene in transgenic mice using inducible promoters resulted in abnormalities of the liver, spleen and hematopoiesis. Similarly, mice infected with an adenovirus carrying the gene had enlarged livers with sinusoidal cell proliferation. The spleen was similarly affected and the mice showed abnormalities in platelet counts. The protein stimulated aortal outgrowth in vitro about as effectively as other growth factors tested with fibroblasts and smooth muscle cells being the most affected. The protein stimulated intracellular calcium release in these cells.

L3 ANSWER 39 OF 41 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:	2000:335442 CAPLUS
DOCUMENT NUMBER:	133:1492
TITLE:	Human platelet-derived growth factor D, its cDNA sequences, and uses thereof in medical and diagnostic applications
INVENTOR(S):	Eriksson, Ulf; Aase, Karin; Ponten, Annica; Lee, Xuri; Uutela, Marko; Alitalo, Kari; Oestman, Arne; Heldin, Carl-Henrik
PATENT ASSIGNEE(S):	Ludwig Institute for Cancer Research, USA; Helsinki University Licensing Ltd. Oy (FI/FI)
SOURCE:	PCT Int. Appl., 111 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	4
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000027879	A1	20000518	WO 1999-US26462	19991110
W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO,				

NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2349951	AA	20000518	CA 1999-2349951		19991110
EP 1129110	A1	20010905	EP 1999-958854		19991110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
JP 2002534061	T2	20021015	JP 2000-581056		19991110
NZ 511379	A	20030630	NZ 1999-511379		19991110
AU 770899	B2	20040304	AU 2000-16136		19991110
PRIORITY APPLN. INFO.:			US 1998-107852P	P	19981110
			US 1998-113997P	P	19981228
			US 1999-150604P	P	19990826
			US 1999-157108P	P	19991004
			US 1999-157756P	P	19991005
			WO 1999-US26462	W	19991110

AB **PDGF-D**, a new member of the PDGF/VEGF family of growth factors, is described, as well as the nucleotide sequence encoding it, methods for producing it, **antibodies** and other antagonists to it, transfected and transformed host cells expressing it, pharmaceutical compns. containing it, and uses thereof in medical and diagnostic applications.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 40 OF 41 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:227431 CAPLUS
DOCUMENT NUMBER: 132:261098
TITLE: Human and murine platelet-derived growth factor C and their cDNA sequences and biological activities
INVENTOR(S): Eriksson, Ulf; Aase, Karin; Lee, Xuri; Ponten, Annica; Uutela, Marko; Alitalo, Kari; Oestman, Arne; Heldin, Carl-Henrik; Betsholz, Christer
PATENT ASSIGNEE(S): Ludwig Institute for Cancer Research, USA; Helsinki University Licensing Ltd.
SOURCE: PCT Int. Appl., 135 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2000018212	A2	20000406	WO 1999-US22668		19990930
W: AE, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2344561	AA	20000406	CA 1999-2344561		19990930
EP 1123408	A1	20010816	EP 1999-952989		19990930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
JP 2002525086	T2	20020813	JP 2000-571742		19990930
PRIORITY APPLN. INFO.:			US 1998-102461P	P	19980930
			US 1998-108109P	P	19981112
			US 1998-110749P	P	19981203
			US 1998-113002P	P	19981218
			US 1999-135426P	P	19990521

US 1999-144022P P 19990715
WO 1999-US22668 W 19990930

AB The invention provides isolated novel growth factors which have the ability to stimulate and/or enhance proliferation or differentiation and/or growth and/or motility of cells expressing platelet-derived growth factor C receptor. The cDNA and deduced amino acid sequences are provided for human and murine platelet-derived growth factor C (**PDGF-C**). Also provided are vectors and host cells expressing **PDGF-C**, **antibodies**, and heterodimers with other PDGF factors or vascular endothelial growth factor subunits. **PDGF-C** may be used to stimulate growth of connective tissue or wound healing, promoting fibroblast mitogenesis, inducing PDGF α-receptor activating, inhibiting tumor growth and identifying specific types of tumor, screening antagonists, inhibiting tissue remodeling during invasion of tumor cells, and treating fibrotic conditions.

L3 ANSWER 41 OF 41 MEDLINE on STN DUPLICATE 9
ACCESSION NUMBER: 86000696 MEDLINE
DOCUMENT NUMBER: PubMed ID: 2994752
TITLE: Cultured endothelial cells do not respond to a platelet-derived growth-factor-like protein in an autocrine manner.
AUTHOR: Kazlauskas A; DiCorleto P E
CONTRACT NUMBER: HL-29582 (NHLBI)
M01 RR00210 (NCRR)
SOURCE: Biochimica et biophysica acta, (1985 Sep 30) 846 (3) 405-12.
Journal code: 0217513. ISSN: 0006-3002.
PUB. COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198510
ENTRY DATE: Entered STN: 19900321
Last Updated on STN: 20000303
Entered Medline: 19851031

AB Cultured endothelial cells produce a growth factor similar or identical to platelet-derived growth factor (PDGF). Endothelial cells are able to proliferate in plasma-supplemented medium, while most nontransformed cells require serum-supplemented medium. Since PDGF is a major serum mitogen, we have tested the possibility that endothelial cells interact with and respond to the autologously produced PDGF-like (**PDGF-c**) protein. We have found that bovine aortic and rat heart endothelial cells express little or no cell surface PDGF receptors as determined by binding of pure 125I-PDGF. Treating these cells under acidic conditions, which release receptor-bound PDGF in control cells without affecting receptor function, did not reveal a population of cryptic receptors. In addition, when rat heart endothelial cells were grown in the presence of an **antibody** to PDGF, proliferation was unimpaired, though no detectable free PDGF was present in the medium. An equivalent amount of **antibody** completely blocked the mitogenic response of human fibroblasts that had been preincubated for 1 h at 37 degrees C with an equivalent dose of PDGF. Thus, endothelial cells do not respond mitogenically in a manner that would be expected from the interaction of autologously produced PDGF with its cell surface receptor. Endothelial cells were detergent-solubilized and immobilized on nitrocellulose in an attempt to detect the presence of intracellular PDGF receptors. Specific binding of 125I-PDGF to adsorbed, solubilized bovine aortic or rat heart endothelial cells was undetectable, though significant binding to adsorbed, solubilized fibroblasts, used as a positive control, was observed. We conclude that endothelial cells do not have detectable intracellular PDGF receptors.

```
=> FIL STNGUIDE
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                        49.13      49.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                        -6.57      -6.57

FILE 'STNGUIDE' ENTERED AT 11:04:01 ON 16 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Dec  9, 2005 (20051209/UP).

=> dis ibib abs l3 20-29
YOU HAVE REQUESTED DATA FROM FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS' - CONTINUE?
(Y)/N:y


L3   ANSWER 20 OF 41  CAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:        2003:892428  CAPLUS
DOCUMENT NUMBER:         139:359243
TITLE:                   Compositions and methods for modulating vasculogenesis
                         or angiogenesis with platelet-derived growth factor C
                         (PDGF-C) core protein domain
INVENTOR(S):             Li, Xuri; Eriksson, Ulf; Carmeliet, Peter; Collen,
                         Desire
PATENT ASSIGNEE(S):      Ludwig Institute for Cancer Research, USA
SOURCE:                  U.S. Pat. Appl. Publ., 82 pp., Cont.-in-part of U.S.
                         Ser. No. 410,349.
                         CODEN: USXXCO
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  5
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     --------------      ----   --------    --------------------     --------
     US 2003211994        A1    20031113    US 2002-303997           20021126
     US 2004053837        A1    20040318    US 2003-439337           20030516
PRIORITY APPLN. INFO.:                      US 1998-102461P      P   19980930
                                            US 1998-108109P      P   19981112
                                            US 1998-110749P      P   19981203
                                            US 1998-113002P      P   19981218
                                            US 1999-135426P      P   19990521
                                            US 1999-144022P      P   19990715
                                            US 1999-410349       A2  19990930
                                            US 2002-303997       A2  20021126
AB   A method for modulating vasculogenesis or angiogenesis using the core
     domain protein of PDGF-C, a new member of the
     PDGF/VEGF family of growth factors, or a homodimer or a heterodimer
     comprising the core domain.  Also disclosed are pharmaceutical compns.
     comprising the core protein, nucleotide sequences encoding the protein,
     and uses thereof in medical and diagnostic applications.

L3   ANSWER 21 OF 41  CAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:        2003:334533  CAPLUS
DOCUMENT NUMBER:         138:349060
TITLE:                   Methods for the production and regulation of the
```

receptor-binding specificity of platelet-derived growth factor C for the treatment of ischemia, hypertrophy, fibrosis and tumorgenesis

INVENTOR(S): Eriksson, Ulf; Fredriksson, Linda
PATENT ASSIGNEE(S): Swed.
SOURCE: U.S. Pat. Appl. Publ., 68 pp., Cont.-in-part of U.S. Ser. No. 852,209.
CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2003082670	A1	20030501	US 2002-131600		20020425
US 2002164687	A1	20021107	US 2001-852209		20010510
PRIORITY APPLN. INFO.:			US 1998-102461P	P	19980930
			US 1998-108109P	P	19981112
			US 1998-110749P	P	19981203
			US 1998-113002P	P	19981218
			US 1999-135426P	P	19990521
			US 1999-144022P	P	19990715
			US 1999-410349	A2	19990930
			US 2001-852209	A2	20010510

AB **PDGF-C**, a new member of the PDGF/VEGF family of growth factors, is described, as well as nucleotide sequences, its method of production, **antibodies** and antagonists. Also disclosed are transfected and transformed host cells expressing same and pharmaceutical compns., and uses thereof in medical and diagnostic applications. Proteolytic processing of **PDGF-C** is accomplished by a serine protease. Methods for inhibiting **PDGF-C** activities and for treating disease caused by **PDGF-C** over-activity of over-expression are also disclosed. Exemplified are the production of anti-**PDGF-C antibodies**, VEGF and PDGF receptor subtypes binding ability and localization in the developing mouse embryo. Ability of **PDGF-C** to induce angiogenesis is also exemplified, with addnl. assays to be performed for the assessment of this PDGF-induced angiogenesis.

L3 ANSWER 22 OF 41 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:300603 CAPLUS
DOCUMENT NUMBER: 138:326530
TITLE: Method for stimulating connective tissue growth or wound healing
INVENTOR(S): Uutela, Marko; Eriksson, Ulf; Alitalo, Kari
PATENT ASSIGNEE(S): Finland
SOURCE: U.S. Pat. Appl. Publ., 47 pp., Cont.-in-part of U.S. Ser. No. 86,623.
CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2003073637	A1	20030417	US 2002-260539		20021001
US 6706687	B1	20040316	US 1999-438046		19991110
US 2002164710	A1	20021107	US 2002-86623		20020304
US 2005209136	A1	20050922	US 2004-794392		20040308
PRIORITY APPLN. INFO.:			US 1998-107852P	P	19981110
			US 1998-113997P	P	19981228
			US 1999-150604P	P	19990826

US 1999-157108P	P	19991004
US 1999-157756P	P	19991005
US 1999-438046	A2	19991110
US 2000-691200	B2	20001019
US 2002-86623	A2	20020304
US 2002-260539	A2	20021001

AB The invention features **PDGF-D**, a new member of the PDGF/VEGF family of growth factors, as well as the nucleotide sequence encoding it, methods for producing it, **antibodies** and other antagonists to it, transfected and transformed host cells expressing it, pharmaceutical compns. containing it, and uses thereof in medical and diagnostic applications, including methods for stimulating growth of a connective tissue or healing a wound in a mammal, which methods comprise administering to the mammal an effective amount of **PDGF-D** polypeptides or polynucleotides encoding the **PDGF-D** polypeptides.

L3 ANSWER 23 OF 41 EMBASE COPYRIGHT (c) 2005 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2003268470 EMBASE
TITLE: Platelet-derived growth factor (**PDGF**)-C, a PDGF family member with a vascular endothelial growth factor-like structure.
AUTHOR: Reigstad L.J.; Sande H.M.; Fluge O.; Bruland O.; Muga A.; Varhaug J.E.; Martinez A.; Lillehaug J.R.
CORPORATE SOURCE: J.R. Lillehaug, Dept. of Molecular Biology, HIB, University of Bergen, Thormohlensgate 55, N-5020 Bergen, Norway. johan.lillehaug@mbi.uib.no
SOURCE: Journal of Biological Chemistry, (9 May 2003) Vol. 278, No. 19, pp. 17114-17120.
Refs: 48
ISSN: 0021-9258 CODEN: JBCHA3
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 004 Microbiology
029 Clinical Biochemistry
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 20030724
Last Updated on STN: 20030724

AB Platelet-derived growth factor (**PDGF**)-C is a novel member of the PDGF family that binds to PDGF αα and αβ receptors. The growth factor domain of **PDGF-C** (GFD-**PDGF-C**) was expressed in high yields in Escherichia coli and was purified and refolded from inclusion bodies obtaining a biologically active growth factor with dimeric structure. The GFD-**PDGF-C** contains 12 cysteine residues, and Ellman assay analysis indicates that it contains three intramonomeric disulfide bonds, which is in accordance with GFD-**PDGF-C** being a member of the cystine knot superfamily of growth factors. The recombinant GFD-**PDGF-C** was characterized by CD, fluorescence, NMR, and infrared spectroscopy. Together, our data indicate that GFD-**PDGF-C** is a highly thermostable protein that contains mostly β-sheet secondary structure and some (6%) α-helix structure. The structural model of **PDGF-C**, obtained by homology-based molecular modeling using the structural representatives of this family of growth factors, shows that GFD-**PDGF-C** has a higher structural homology to the vascular endothelial growth factor than to PDGF-B. The modeled structure can give further insights into the function and specificity of this molecule.

L3 ANSWER 24 OF 41 MEDLINE on STN DUPLICATE 5

ACCESSION NUMBER: 2003398231 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12937299

TITLE: A fully human monoclonal **antibody** (CR002) identifies **PDGF-D** as a novel mediator of mesangioproliferative glomerulonephritis.
AUTHOR: Ostendorf Tammo; van Roeyen Claudia R C; Peterson Jeffrey D; Kunter Uta; Eitner Frank; Hamad Avin J; Chan Gerlinde; Jia Xiao-Chi; Macaluso Jennifer; Gazit-Bornstein Gadi; Keyt Bruce A; Lichenstein Henri S; LaRochelle William J; Floege Jurgen
CORPORATE SOURCE: Division Nephrology, University of Aachen, Germany.
SOURCE: Journal of the American Society of Nephrology : JASN, (2003 Sep) 14 (9) 2237-47.
Journal code: 9013836. ISSN: 1046-6673.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200402
ENTRY DATE: Entered STN: 20030826
Last Updated on STN: 20040205
Entered Medline: 20040204

AB PDGF-B is of central importance in mesangioproliferative diseases. **PDGF-D**, a new PDGF isoform, like PDGF-B, signals through the PDGF betabeta-receptor. The present study first determined that **PDGF-D** is mitogenic for rat mesangial cells and is not inhibited by a PDGF-B antagonist. Low levels of **PDGF-D** mRNA were detected in normal rat glomeruli. After induction of mesangioproliferative nephritis in rats by anti-Thy 1.1 mAb, glomerular **PDGF-D** mRNA and protein expression increased significantly from days 4 to 9 in comparison with nonnephritic rats. Peak expression of **PDGF-D** mRNA occurred 2 d later than peak PDGF-B mRNA expression. In addition, **PDGF-D** serum levels increased significantly in the nephritic animals on day 7. For investigating the functional role of **PDGF-D**, neutralizing fully human mAb were generated using the XenoMouse technology. Rats with anti-Thy 1.1-induced nephritis were treated on days 3 and 5 with different amounts of a fully human PDGF-DD-specific neutralizing mAb (CR002), equal amounts of irrelevant control mAb, or PBS by intraperitoneal injection. Specific antagonism of **PDGF-D** led to a dose-dependent (up to 67%) reduction of glomerular cell proliferation. As judged by double immunostaining for 5-bromo-2'-deoxyuridine and alpha-smooth muscle actin, glomerular mesangial cell proliferation was reduced by up to 57%. Reduction of glomerular cell proliferation in the rats that received CR002 was not associated with reduced glomerular expression of PDGF-B mRNA. **PDGF-D** antagonism also led to reduced glomerular infiltration of monocytes/macrophages (day 5) and reduced accumulation of fibronectin (day 8). In contrast, no effect was noted in normal rats that received an injection of CR002. These data show that **PDGF-D** is overexpressed in mesangioproliferative states and can act as an auto-, para-, or even endocrine glomerular cell mitogen, indicating that antagonism of **PDGF-D** may represent a novel therapeutic approach to mesangioproliferative glomerulonephritides.

L3 ANSWER 25 OF 41 MEDLINE on STN DUPLICATE 6
ACCESSION NUMBER: 2003188236 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12707385
TITLE: **PDGF-C** expression in the developing and normal adult human kidney and in glomerular diseases.
AUTHOR: Eitner Frank; Ostendorf Tammo; Kretzler Matthias; Cohen Clemens D; Eriksson Ulf; Grone Hermann-Josef; Floege Jurgen
CORPORATE SOURCE: Division of Nephrology and Immunology, Aachen University, Pauwelsstrasse 30, 52074 Aachen, Germany. (ERCB-Consortium). feitner@ukaachen.de
SOURCE: Journal of the American Society of Nephrology : JASN, (2003

May) 14 (5) 1145-53.
Journal code: 9013836. ISSN: 1046-6673.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200306
ENTRY DATE: Entered STN: 20030423
Last Updated on STN: 20030626
Entered Medline: 20030625

AB PDGF-C is a new member of the PDGF-family and has recently been identified as a rat mesangial cell mitogen. Its expression and function in human kidneys is unknown. Localization of PDGF-C protein was analyzed by immunohistochemistry using a rabbit polyclonal antibody directed against the core-domain of PDGF-C in human fetal kidneys (n = 8), normal adult human kidneys (n = 9), and in renal biopsies of patients with IgA nephropathy (IgAN, n = 31), membranous nephropathy (MGN, n = 8), minimal change disease (MC, n = 7), and transplant glomerulopathy (TxG, n = 12). Additionally, PDGF-C mRNA was detected in microdissected glomeruli by real-time RT-PCR in cases of normal adult kidneys (n = 7), IgAN (n = 27), MGN (n = 11), and MC (n = 13). In the fetal kidney, PDGF-C localized to the developing mesangium, ureteric bud epithelium, and the undifferentiated mesenchyme. In the adult kidney, PDGF-C was constitutively expressed in parietal epithelial cells of Bowman's capsule, tubular epithelial cells (loops of Henle, distal tubules, collecting ducts), and in arterial endothelial cells. A marked upregulation of glomerular PDGF-C protein was seen in MGN and TxG with a prominent positivity of virtually all podocytes. In MC, PDGF-C localized to podocytes in a more focal distribution. In MGN, increased glomerular PDGF-C protein expression was due to increased mRNA synthesis as a 4.3-fold increase in PDGF-C mRNA was detected in microdissected glomeruli from MGN compared with normal. PDGF-C protein was additionally expressed in individual mesangial cells in TxG. Finally, upregulated PDGF-C protein expression was detected within sclerosing glomerular and fibrosing tubulointerstitial lesions in individual cases from all analyzed groups. We conclude that PDGF-C is constitutively expressed in the human kidney and is upregulated in podocytes and interstitial cells after injury/activation of these cells.

L3 ANSWER 26 OF 41 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 2003:71118 BIOSIS
DOCUMENT NUMBER: PREV200300071118
TITLE: Growth factor homolog ZVEGF4.
AUTHOR(S): Gilbert, Teresa [Inventor, Reprint Author]; Hart, Charles E. [Inventor]; Sheppard, Paul O. [Inventor]; Gilbertson, Debra G. [Inventor]
CORPORATE SOURCE: Seattle, WA, USA
ASSIGNEE: ZymoGenetics, Inc.
PATENT INFORMATION: US 6495668 20021217
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Dec 17 2002) Vol. 1265, No. 3. http://www.uspto.gov/web/menu/patdata.html. e-file. ISSN: 0098-1133 (ISSN print).
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 29 Jan 2003
Last Updated on STN: 29 Jan 2003

AB Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. Multimers of the polypeptides are also disclosed. The

polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.

L3 ANSWER 27 OF 41 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:850240 CAPLUS
DOCUMENT NUMBER: 137:363702
TITLE: Platelet-derived growth factor D, DNA coding for it, and pharmaceutical uses
INVENTOR(S): Eriksson, Ulf; Aase, Karin; Li, Xuri; Ponten, Annica; Uutela, Marko; Alitalo, Kari; Oestman, Arne; Heldin, Carl-Henrik
PATENT ASSIGNEE(S): Swed.
SOURCE: U.S. Pat. Appl. Publ., 60 pp., Cont.-in-part of U. S. Ser. No. 691,200, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2002164710	A1	20021107	US 2002-86623		20020304
US 6706687	B1	20040316	US 1999-438046		19991110
US 2003073637	A1	20030417	US 2002-260539		20021001
US 2005209136	A1	20050922	US 2004-794392		20040308
PRIORITY APPLN. INFO.:			US 1998-107852P	P	19981110
			US 1998-113997P	P	19981228
			US 1999-150604P	P	19990826
			US 1999-157108P	P	19991004
			US 1999-157756P	P	19991005
			US 1999-438046	A2	19991110
			US 2000-691200	B2	20001019
			US 2002-86623	A2	20020304
			US 2002-260539	A2	20021001

AB PDGF-D, a new member of the PDGF/VEGF family of polypeptide growth factors, is described, as well as nucleotide sequences encoding, methods for producing, pharmaceutical compns. containing this new growth factor, and its **antibodies** and other antagonists. Also disclosed are transfected and transformed host cells expressing **PDGF-D**, and uses thereof in medical and diagnostic applications. Fragments and homologs of **PDGF-D** are also covered by the invention.

L3 ANSWER 28 OF 41 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:850239 CAPLUS
DOCUMENT NUMBER: 137:364421
TITLE: Protein and cDNA sequences of a novel human growth factor sequence homolog
INVENTOR(S): Shigeta, Ron T.; Siani-Rose, Michael A.
PATENT ASSIGNEE(S): Affymetrix, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 45 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2002164709	A1	20021107	US 2002-83853		20020226
PRIORITY APPLN. INFO.:			US 2001-272663P	P	20010301

AB The present invention provides protein and cDNA sequences of a novel human

protein which has sequence homol. with vascular endothelial growth factor, **fallotein** and platelet derived growth factor. Also provided by the invention are host cells and transgenic organisms comprising the gene delivery vehicle of the present invention. Also provided by the invention are computer readable media containing the polynucleotide or polypeptide sequences of the present invention. Further provided are methods of using these compns. for diagnosis and treatment of growth factor associated diseases.

L3 ANSWER 29 OF 41 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:850230 CAPLUS
DOCUMENT NUMBER: 137:363701
TITLE: Platelet-derived growth factor C, DNA encoding it and its therapeutic and diagnostic uses
INVENTOR(S): Eriksson, Ulf; Aase, Karin; Li, Xuri; Ponten, Annica; Uutela, Marko; Alitalo, Kari; Oestman, Arne; Heldin, Carl-Henrik; Betsholtz, Christer
PATENT ASSIGNEE(S): Swed.
SOURCE: U.S. Pat. Appl. Publ., 82 pp., Cont.-in-part of U. S. Ser. No. 410,349.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2002164687	A1	20021107	US 2001-852209		20010510
US 2003082670	A1	20030501	US 2002-131600		20020425
PRIORITY APPLN. INFO.:			US 1998-102461P	P	19980930
			US 1998-108109P	P	19981112
			US 1998-110749P	P	19981203
			US 1998-113002P	P	19981218
			US 1999-135426P	P	19990521
			US 1999-144022P	P	19990715
			US 1999-410349	A2	19990930
			US 2001-852209	A2	20010510

AB **PDGF-C**, a new member of the PDGF/VEGF family of growth factors, is described, as well as the nucleotide sequence encoding it, methods for producing it, **antibodies** and other antagonists to it, transfected and transformed host cells expressing it, pharmaceutical compns. containing it, and uses thereof in medical and diagnostic applications. More specifically, the novel growth factor has the ability to stimulate and/or enhance proliferation or differentiation and/or growth and/or motility of cells expressing a **PDGF-C** receptor including, but not limited to, endothelial cells, connective tissue cells, myofibroblasts and glial cells,. Fragments and homologs of **PDGF -C** are also covered by the invention.

```
=> s l1 and glomerulonephritis
             0 ZVEGF4
             0 PDGF
            16 C
             0 PDGF(W) C
             0 FALLOTEIN
             0 SCDGFB
             0 SCDGF
            35 B
             0 SCDGF(W) B
             0 PDGF
            27 D
             0 PDGF(W) D
```

```
              0 ZVEGF3
              0 GLOMERULONEPHRITIS
L4            0 L1 AND GLOMERULONEPHRITIS

=> s l1 and fibrosis
              0 ZVEGF4
              0 PDGF
             16 C
              0 PDGF(W) C
              0 FALLOTEIN
              0 SCDGFB
              0 SCDGF
             35 B
              0 SCDGF(W) B
              0 PDGF
             27 D
              0 PDGF(W) D
              0 ZVEGF3
              0 FIBROSIS
L5            0 L1 AND FIBROSIS
```